Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




An Inexpensive, Disposable Electrochemical Sensor for Detection of Bacteria in Chronic Wounds

By LabMedica International staff writers
Posted on 23 Feb 2016
A recent paper described an inexpensive, disposable electrochemical sensor for the detection of bacteria in chronic wounds.

Investigators at George Washington University (Washington DC, USA) developed the sensor under the auspices of the WE-HEAL Study, which focuses on the interplay of the host immune response and the wound bed microbiome in patients with chronic wounds.

The investigators pointed out that in the field of wound care there was a compelling need to develop rapid alternatives for bacterial identification in the clinical setting, where it generally takes over 24 hours to receive a positive identification. More...
Even new molecular and biochemical identification methods require an initial incubation period of several hours to obtain a sufficient number of cells prior to performing the analysis.

In the current study, the investigators the used an inexpensive, disposable electrochemical sensor to detect pyocyanin, a unique, redox-active quorum sensing molecule released by Pseudomonas aeruginosa, in wound fluid from patients with chronic wounds. By measuring the metabolite excreted by the cells, this electrochemical detection strategy eliminated sample preparation, required less than a minute to complete, and needed only 7.5 microliters of sample to complete the analysis.

The results obtained by the electrochemical technique were compared against 16S rRNA profiling using the 454 pyrosequencing method. Blind identification yielded nine correct matches, two false negatives, and three false positives, giving a sensitivity of 71% and specificity of 57% for detection of Pseudomonas.

"Being able to detect Pseudomonas and other infectious organisms at the time of the clinic visit will greatly enhance our ability to take care of patients," said senior author Dr. Victoria Shanmugam, director of the division of rheumatology at George Washington University. "We would not have to wait for culture results before making a decision about antibiotics, and this would allow us to better tailor therapies for our patients. Infections are a major challenge in medicine, and by using this probe, we were able to harness one of the unique molecules produced by bacteria to detect infection. We plan to continue to refine this testing method and hope to scale it up for detection of other bacteria and to optimize it for clinical use."

The method was described in the January 27, 2016, online edition of the journal Wound Repair and Regeneration.

Related Links:

George Washington University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.